BI wants to 'own' lung therapy space as India-priced afatinib debuts
This article was originally published in Scrip
"We want to own the lung cancer therapy space," is how Boehringer Ingelheim (BI) India's managing director Sharad Tyagi refers to the family-owned German multinational's ambitions in the segment with the introduction of its first oncology product, afatinib, on the domestic market.
You may also be interested in...
The new leader at Boehringer Ingelheim India has a full plate and significant expectations riding on her to sustain momentum at one of the fastest-growing foreign pharma firms in the country.
Glenmark and Sun Pharma introduce nintedanib generics in India at a fraction of the innovator product’s price, vying for a share of the IPF market where pirfenidone currently holds sway.
The CEO of Biocon’s biosimilars subsidiary has unexpectedly departed the role. Management stresses there is no disruption to its "strategic intent", but COVID-19 has "dampened" the arm’s push to reach its aspirational $1bn revenue target by 2022.